Vivozon Pharmaceutical said on the 7th that it signed a contract with Hanmi Pharmaceutical for joint marketing cooperation of the non-opioid analgesic "Onapra Injection (Onapra)."
Under the contract, the two companies will cooperate on distribution, sales, and marketing of Onapra for medical institutions with 300 beds or fewer. Vivozon Pharmaceutical will supply the finished goods of Onapra, and Hanmi Pharmaceutical will use its hospital sales network to target the mid-sized hospital market.
Onapra is a non-opioid analgesic injection used to manage moderate to severe acute pain after surgery. In Dec. 2024, it received item approval for Onapra as Korea's 38th domestically developed new drug from the Ministery of Food and Drug Safety. Onapra posted about 2.87 billion won in sales two months after its launch last year.
A company official said, "Through collaboration with Hanmi Pharmaceutical, we expect to rapidly expand access to Onapra, focusing on the mid-sized hospital market with 300 beds or fewer," adding, "Amid growing demand in clinical settings for non-opioid analgesics, we will provide a treatment option with safety and efficacy and lead the market."